Day: May 8, 2025

– Esperion to Receive an Upfront Payment, Near-Term Milestones and Tiered Royalties on Product Sales – – Further Expands Global Access to Bempedoic Acid Products and Provides Opportunity to Bring Innovative Preventative Therapy to 2.6 million Canadians Living with Diagnosed Heart Disease – ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) — Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with HLS Therapeutics (TSX:HLS) for the exclusive rights to commercialize NEXLETOL* and NEXLIZET* in Canada. Under the terms of the agreement, Esperion will receive an upfront payment, near-term milestone and tiered royalties on product sales. Esperion will be responsible for supplying finished product to HLS Therapeutics at a profitable transfer price. According to the Government of Canada,...

Awaiting FDA action on YUTREPIA™ NDA with a PDUFA goal date of May 24, 2025 District Court dismissed cross claim filed by United Therapeutics challenging PH-ILD amendment Fully enrolled Cohort A of ASCENT study in patients with PH-ILD Further strengthened financial position via access of up to $100 million from existing financing agreement with HealthCare Royalty Company to host webcast today at 8:30 a.m. ETMORRISVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the first quarter ended March 31, 2025. The company will also host a webcast at 8:30 a.m. ET on May 8, 2025 to discuss its financial results and provide a corporate update. Dr. Roger Jeffs,...

–Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 — –Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of calendar 2025 — –With positive Phase 2b QUALITY study, Veru plans for end of Phase 2 meeting with FDA to discuss Phase 3 clinical program — –Company to host conference call and webcast today at 8:00 a.m. ET– MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for its fiscal 2025 second quarter and provided an update on progress of its clinical development programs. “In addition...

Singapore, May 08, 2025 (GLOBE NEWSWIRE) — Webuy Global Ltd. (Nasdaq: WBUY), a forward-thinking, technology-driven e-commerce and travel platform in Southeast Asia, today announced that the Company has been successfully reinstated on the Nasdaq Capital Market (“Nasdaq”), effective May 8, 2025. The relisting follows confirmation from Nasdaq that the Company has regained compliance with the minimum bid price requirement under Rule 5550(a)(2). Webuy’s return to Nasdaq  is a pivotal milestone in its broader turnaround. After implementing a comprehensive recovery strategy, which included reverse stock splits and a successful appeal before the Nasdaq Hearing Panel , the company has regained full compliance. This achievement underscores Webuy’s continued operational momentum and hopes to lead to renewed investor confidence in its growth...

ASIC fleet upgrade drives 79% increase in hashrate and 37% improvement in fleet efficiency quarter-over-quarter Launch of American Bitcoin accelerates Hut 8’s evolution as an integrated energy infrastructure platform Earnings Release HighlightsRevenue of $21.8 million, net loss of $134.3 million, and Adjusted EBITDA of ($117.7) million. Total energy capacity under management of 1,020 megawatts (“MW”) as of March 31, 2025. ~10,800 MW development pipeline with ~2,600 MW of capacity under exclusivity as of March 31, 2025. Strategic Bitcoin reserve of 10,264 Bitcoin with a market value of $847.2 million as of March 31, 2025.MIAMI, May 08, 2025 (GLOBE NEWSWIRE) — Hut 8 Corp. (Nasdaq | TSX: HUT) (“Hut 8” or the “Company”), an energy infrastructure platform integrating power, digital infrastructure, and compute at scale to fuel next-generation,...

BOSTON HEIGHTS, Ohio, May 08, 2025 (GLOBE NEWSWIRE) — Arhaus, Inc. (“Arhaus” or the “Company”) (NASDAQ: ARHS), a growing lifestyle brand and omni-channel retailer of premium artisan-crafted home furnishings, reported first quarter 2025 results for the period ended March 31, 2025. Highlights include:Net revenue increased 5.5% to $311 million compared to the same period in 2024 Gross margin increased 0.4% to $116 million compared to the same period in 2024 Selling, general and administrative expenses increased 13.9% to $110 million compared to the same period in 2024 Net and comprehensive income decreased 67.6% to $5 million compared to the same period in 2024 Adjusted EBITDA decreased 36.2% to $19 million compared to the same period in 2024 Comparable growth(1) of (1.5)% Demand comparable growth(2) of 4.1% Total Showroom Projects(3)...

Lánasjóður sveitarfélaga hefur ákveðið að efna til útboðs á skuldabréfaflokkunum LSS 39 0303 og LSS151155 mánudaginn 12. maí 2025. Lánasjóðurinn stefnir að því að taka tilboðum að fjárhæð 500 til 1.500 milljónir króna að nafnvirði í skuldabréfaflokknum LSS151155 og að fjárhæð 500 til 1.500 milljónir króna að nafnvirði í skuldabréfaflokknum LSS 39 0303. Lánasjóðurinn áskilur sér rétt til að hækka og lækka útboðsfjárhæð útboðsins, taka hvaða tilboði sem er eða hafna þeim öllum. Lánasjóðurinn hefur boðið aðalmiðlurum sjóðsins Arion banka, Íslandsbanka, Kviku banka, Landsbankanum og Fossum fjárfestingabanka að taka þátt í útboðinu.  Óskað er eftir tilboðum í samræmi við eftirfarandi lýsingu: Fyrirkomulag: “Hollensk” uppboðsaðferð þar sem allir tilboðsgjafar fá sömu ávöxtunarkröfu og hæst er tekið. Heimilt er að afturkalla eða breyta tilboði...

Consolidated net revenue of € 680.0 million in the first quarter of 2025, +11.9% or +7.2% on a like-for-like basis(3) and at constant exchange rates (CER) EBITDA(1) of € 270.2 million, +10.7%, margin on revenue of 39.7%        Adjusted net income(2) of € 175.5 million, +7.2%Net income of € 125.0 million, +1.2%Free cash flow(4) of € 158.8 million, +€ 11.7 million vs prior year Net debt(5) at € 2,020.8 million, just below 2.2x EBITDA pro-forma(6) Isturisa® granted expanded approval by the FDA for the treatment of endogenous hypercortisolemia in adults with Cushing’s syndrome, supporting peak year sales increase to € 550-650 million; Signifor® LAR approved in China for the treatment of patients with acromegaly FY 2025 financial targets confirmed Positive momentum of the Group expected to continue as reflected in the FY 2027 financial...